Log in to search using one of your social media accounts:

 

Chinese researchers report first lung stem cell transplantation clinical trial

A research team from Tongji University in China have made a breakthrough in human lung regeneration technology. For the first time, researchers have regenerated patients' damaged lungs using autologous lung stem cell transplantation in a pilot clinical trial. The study can be found in the open access journal Protein &Cell which is published by Springer Nature.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

In conclusion, a debate exists on whether aging is a disease in itself. Some authors suggest that physiological aging (or senescence) is not really distinguishable from pathology, while others argue that aging is different from age-related diseases and other pathologies. It is interesting to stress that the answer to this question has important theoretical and practical consequences, taking into account that various strategies capable of setting back the aging clock are emerging. The most relevant consequence is that, if we agree that aging is equal to disease, all human beings have to be considered as patients to be treat...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
The week of April 23-27 has been designated as National Pediatric Transplant Week.  This week is to bring attention to the great need for organ donations and to honor  donors and their families whose incredibly selfless gift has given someone the gift of life.While most of us will never experience the need for a transplant, there are many of us who know someone who has a debilitating condition such as kidney dialysis that are in need of a transplant.Right now there are almost 2,000 children on the national transplant list.  Those needing hearts, lungs, eyes, tissue, liver, kidney, or some other body part are...
Source: Pediatric Health Associates - Category: Pediatrics Tags: Volunteer Opportunities Source Type: news
Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea Sponsor:   Paul Szabolcs Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study demonstrates that small peptide domains derived from native protein amelogenin can be utilized to construct a mineral layer on damaged human enamel in vitro. Six groups were prepared to carry out remineralization on artificially created lesions on enamel: (1) no treatment, (2) Ca2+ and PO43- only, (3) 1100 ppm fluoride (F), (4) 20 000 ppm F, (5) 1100 ppm F and peptide, and (6) peptide alone. While the 1100 ppm F sample (indicative of common F content of toothpaste for homecare) did not deliver F to the thinly deposited mineral layer, high F test sample (indicative of clinical varnish treatment) formed mainly C...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 12 February 2018 Source:Respiratory Investigation Author(s): Ayako Shimada, Jiro Terada, Kenji Tsushima, Yoshihisa Tateishi, Ryuzo Abe, Shigeto Oda, Motomu Kobayashi, Masaomi Yamane, Takahiro Oto, Koichiro Tatsumi Cases of extracorporeal membrane oxygenation (ECMO) bridged lung transplantation (LTx) are rare in Japan because an allocation system to prioritize patients based on urgency remains to be established. For critically ill patients who cannot wait for a brain-dead donor LTx, ECMO bridge to living-donor LTx may be the only practical option. A 21-year-old woman with pleuroparenchyma...
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Conclusions We here demonstrate for the first time that pulmonary transplantation of human iPSC-derived macrophages leads to pulmonary engraftment, their in situ differentiation to an AM phenotype and a reduction of alveolar proteinosis in a humanized PAP model. To our knowledge, this finding presents the first proof-of-concept for the therapeutic potential of iPSC-derived cells in a pulmonary disease and may have profound implications beyond the rare disease of PAP. PMID: 29652170 [PubMed - as supplied by publisher]
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Am J Respir Crit Care Med Source Type: research
We describe our unique approach of aiming for ASCT one year after HT so that patients can remain in hematological remission with current chemotherapy and to allow patients complete recovery from OHT.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Heart transplantation remains the standard treatment for end stage heart failure patients. However, hemodynamic instability after brain death (BD) could affect posttransplant graft function. Conditioned medium (CM) from bone marrow derived mesenchymal stem cells (MSCs) was found to protect the myocardium against ischemia/reperfusion (IR), this finding appears to be mediated via activation of the phosphatidylinositol 3 kinase (PI3K) signalling. We hypothesized that CM added to a preservation solution (Custodiol) improves in vivo left ventricular (LV) graft function after transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Ex vivo lung perfusion (EVLP) has emerged as a modern preservation technique developed to evaluate candidate donor lungs in a normothermic and metabolically active state. Donor leukocytes are linked to the development of transplant related ischemia reperfusion injury, primary graft dysfunction, and acute rejection. Pharmacologic strategies to enhance donor leukocyte depletion during EVLP have not yet been described. Plerixafor (Mozobil) is a clinically available CXCR4 receptor antagonist, which disrupts the interaction between CXCR4 and SDF-1 α and facilitates mobilization of hematopoietic stem cells into peripheral circulation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
More News: China Health | Clinical Trials | Lung Transplant | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Study | Transplants